Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Eeles RA, Dearnaley DP, ArdernJones A, Shearer RJ, Easton DF, Ford D, Edwards S, Dowe A, Anderson J, Archibold J, Bailey M, Barker C, Bellringer J, Bishop DT, Bishop M, Bolger J, Boyd J, Budd D, Butler M, Brookstein R, Charig C, Conn I, Cranston C, Crundwell M, Das G, Doble A, Duncan W, Duchesne J, Eccles D, Fawcett D, Fisher C, Fletcher M, Fowler JW, Gallegos C, Ghaznavi A, Gilbert H, Glaholm J, Gordon E, Hampson S, Hanbury DC, Hargreave T, Harland S, Harrison GS, Harrison NW, Hart JL, Hehir M, Hendry W, Higgins A, Hopper J, Horwich A, Hughes M, Irving S, James N, Jenkins IL, Jones C, Key T, Kaisary A, Kirby R, Kirk D, Lee J, Lemberger R, Lloyd S, Lynch M, Malone PR, Mansi J, Mason M, McEwan AB, McNicholas TA, Moffat LEF, Morgan RJ, Murday V, Muir G, Munson KW, Murray K, Murrell S, Newman H, Oboyle PJ, Odonoghue E, Notley RG, Pengelly A, Philip T, Plail R, Powell C, Russell J, Read G, Reddy PJ, Richmond W, Roberts T, Rowley K, Rouse AD, Russell RM, Ryan P, Senanayake L, Sandhu D, Shridhar P, Shweitzer R, Shearer R, Smith J, Smith P, Stockdale A, Stower M, Thomas P, Terry T, Thurston A, Tullock D, Turner G, Wallace M, Weston P, Whelan P, Whillis D, Wilson R, Williams G, Woodhouse C. Familial prostate cancer: The evidence and the Cancer Research Campaign British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol. 1997;79:8–14. https://doi.org/10.1111/j.1464-410X.1997.tb00795.x.

Article  PubMed  Google Scholar 

De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol. 2011;60(1):106–17. https://doi.org/10.1016/j.eururo.2011.03.055.

Article  CAS  PubMed  Google Scholar 

Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013;63(5):800–9. https://doi.org/10.1016/j.eururo.2012.11.013.

Article  CAS  PubMed  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.

Article  CAS  PubMed  Google Scholar 

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. https://doi.org/10.1038/nature07205.

Article  CAS  PubMed  Google Scholar 

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N, Pathologist G. Multi Center Study, High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology. 1999;54(3):467–72. https://doi.org/10.1016/s0090-4295(99)00152-1.

Article  CAS  PubMed  Google Scholar 

Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol. 2003;43(2):164–75. https://doi.org/10.1016/s0302-2838(02)00548-1.

Article  PubMed  Google Scholar 

Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the relationship between symptoms of prostatitis and histological inflammation: Baseline data from the REDUCE chemoprevention trial. J Urol. 2007;178(3):896–900. https://doi.org/10.1016/j.juro.2007.05.041.

Article  PubMed  Google Scholar 

Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol. 2008;54(6):1379–84. https://doi.org/10.1016/j.eururo.2007.11.026.

Article  PubMed  Google Scholar 

Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA. Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2016;25(3):463–9. https://doi.org/10.1158/1055-9965.epi-15-0987.

Article  CAS  Google Scholar 

Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2014;23(5):847–56. https://doi.org/10.1158/1055-9965.epi-13-1126.

Article  Google Scholar 

Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, Ostrander EA. Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20(5):923–33. https://doi.org/10.1158/1055-9965.epi-10-0994.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davidsson S, Fiorentino M, Andren O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomark Prev. 2011;20(10):2280–7. https://doi.org/10.1158/1055-9965.epi-11-0373.

Article  Google Scholar 

Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, Freedland SJ. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy. Cancer. 2014;120(2):190–6. https://doi.org/10.1002/cncr.28349.

Article  CAS  PubMed  Google Scholar 

Pepe P, Aragona F. Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urol Int. 2011;87(2):171–4. https://doi.org/10.1159/000328043.

Article  PubMed  Google Scholar 

Yli-Hemminki TH, Laurila M, Auvinen A, Maattanen L, Huhtala H, Tammela TLJ, Kujala PM. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int. 2013;112(6):735–41. https://doi.org/10.1111/bju.12153.

Article  CAS  PubMed  Google Scholar 

Langston ME, Horn M, Khan S, Pakpahan R, Doering M, Dennis LK, Sutcliffe S. A systematic review and meta-analysis of associations between clinical prostatitis and prostate cancer: New estimates accounting for detection bias. Cancer Epidemiol Biomark Prev. 2019;28(10):1594–603. https://doi.org/10.1158/1055-9965.epi-19-0387.

Article  Google Scholar 

Vasavada SR, Dobbs RW, Kajdacsy-Balla AA, Abern MR, Moreira DM. Inflammation on prostate needle biopsy is associated with lower prostate cancer risk: A meta-analysis. J Urol. 2018;199(5):1174–81. https://doi.org/10.1016/j.juro.2017.11.120.

Article  PubMed  Google Scholar 

De Marzo AM, Platz EA, Sutcliffe S, Xu JF, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256–69. https://doi.org/10.1038/nrc2090.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solinas C, Chanzá NM, Awada A, Scartozzi M. The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. Cancer Treat Rev. 2017;53:138–45. https://doi.org/10.1016/j.ctrv.2016.12.004.

Article  CAS  PubMed  Google Scholar 

Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60(1):199–215. https://doi.org/10.1111/j.1365-2559.2011.04033.x.

Article  PubMed  PubMed Central  Google Scholar 

Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6(2):87–95. https://doi.org/10.1038/ncpuro1290.

Article  PubMed  Google Scholar 

Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 2018;199(1):161–71. https://doi.org/10.1016/j.juro.2017.08.001.

Article  PubMed  Google Scholar 

Karan D, Dubey S. From inflammation to prostate cancer: The role of inflammasomes. Adv Urol. 2016;2016:3140372. https://doi.org/10.1155/2016/3140372.

Article  PubMed  PubMed Central  Google Scholar 

Brüggemann H, Al-Zeer MA. Bacterial signatures and their inflammatory potentials associated with prostate cancer. APMIS. 2020;128(2):80–91. https://doi.org/10.1111/apm.13021.

Article  PubMed  Google Scholar 

Oseni SO, Naar C, Pavlović M, Asghar W, Hartmann JX, Fields GB, Esiobu N, Kumi-Diaka J. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer. Cancers (Basel). 2023;15(12). https://doi.org/10.3390/cancers15123110.

Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, inflammation, and prostate cancer. J Clin Med. 2019;8(2). https://doi.org/10.3390/jcm8020201.

Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Ann Rev Med. 2013;64:45–47. https://doi.org/10.1146/annurev-med-121211-091527.

Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 2016;118(11):1786–807. https://doi.org/10.1161/circresaha.115.306885.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsing AW, Sakoda LC, Chua SC. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86(3):843S–857S. https://doi.org/10.1093/ajcn/86.3.843S.

Article  CAS  Google Scholar 

Herrero-Aguayo V, Sáez-Martínez P, Jiménez-Vacas JM, Moreno-Montilla MT, Montero-Hidalgo AJ, Pérez-Gómez JM, López-Canovas JL, Porcel-Pastrana F, Carrasco-Valiente J, Anglada FJ, Gómez-Gómez E, Yubero-Serrano EM, Ibañez-Costa A, Herrera-Martínez AD, Sarmento-Cabral A, Gahete MD, Luque RM. Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool. Mol Ther Nucleic Acids. 2022;27:1164–78. https://doi.org/10.1016/j.omtn.2022.02.010.

Article  CAS  PubMed  PubMed Central